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Summary Post-transplant lymphomas or other 
lymphoproliferative lesions, which were 
usually associated with Epstein-Barr virus infections, 
developed in 8, 4, 3, and 2 recipients, respectively, of 
cadaveric kidney, liver, heart, and heart-lung homografts. 
Reduction or discontinuance of immunosuppression caused 
regression of the lesions, often without subsequent rejection 
of the grafts. Chemotherapy and irradiation were not 
valuable. The findings may influence policies about treating 
other kinds of post-transplantation neoplasms. 
Introduction 
AN increased incidence of malignancy, with a dispro-
portionate representation of lymphoreticular tumours, has 
for 15 years 'been a well-recognised complication ofimmuno-
suppression in organ transplant recipients.!,2 The 
dimensions of the hazard have been followed by Penn) 
through a registry to which transplantation surgeons 
throughout the world have contributed. Meanwhile, 
evidence has accumulated that lymphomas in patients with 
natural or iatrogenic immunodeficiency may be associated 
with infection by the Epstein-Barr virus.4 The ominous 
implications of the term lymphoma have been softened by 
calling such tumours "pseudolymphomas"s or "lympho-
proliferative disorders". 6 
In this communication, we describe how lymphopro-
liferative neoplasms that developed under therapy with 
cyclosporin and steroids in renal, hepatic, and cardiac graft 
recipients, underwent resolution ifimmunosuppression was 
reduced or stopped-in contrast to a lethal course no matter 
what else was done in the absence of this simple step. The 
observations have shown that the much publicised cyclo-
sporin lymphomas are relatively innocuous if appropriately 
treated. 
2 
Methods 
Case Material 
17 recipients of various organs had Iymphoproliferative disorders 
two to sixty-eight months after cadaveric organ transplantation 
(table I). The patients were 13 to 62 years old at the time of 
transplantation and had a male/female distribution of 13/4. Donor-
recipient tissue matching was completely random for the non-renal 
transplantations and nearly so in the renal cases. 
The incidence of the Iyrnphoproliferative complications varied 
with the kind of transplant. Between December, 1979, and June I, 
1983, 315 patients were treated with primary or repeat renal 
transplantation, of whom 8 (2' 5%) had lymphoproliferative 
complications. In addition, 129,48, and 6 patients were treated with 
primary liver, heart, and heart-lung transplantations, respectively, 
and in these organ subgroups there were 3, 3, and 2 lympho-
proliferative complications-an incidence in the respective non-
renal organ graft categories of2' 3%, 6· 3%, and 33· 3%. Lymphoid 
lesions subsequently developed in a fourth liver recipient whose 
therapy with azathioprine was changed to cyclosporin 5 years after 
transplantation. 
For the kidney recipients immunosuppression was with cyclo-
sporin and prednisone, as previously described/ 3 of the 4 liver 
recipients were treated similarly.8 The other liver recipient (case 9) 
had had a transplantation on Aug 31, 1977, under azathioprine, 
prednisone, and antilymphocyte globulin (ALG); she was switched 
to cyclosporin and low doses of prednisone in September, 1981, 
because of recurrence in her graft of the chronic active hepatitis that 
had destroyed her native liver. 
In addition to cyclosporin and prednisone, I of the heart and I of 
the heart-lung recipients were given antithymocyte globulin (ATG) 
(table I); both of the heart-lung recipients were treated also with 
azathioprine (table I). 
In several cases the lymphoproliferative lesions gave rise to 
gastrointestinal perforation, obstruction, or haemorrhage (table I). 
Generalised lymphadenopathy and fever were common in a 
syndrome indistinguishable from infectious mononucleosis. 3 
patients(1 kidney, I liver, and I heart recipient) were not diagnosed 
until necropsy, but in the liver recipient (case 10, table I) a cervical 
lymph node biopsy specimen taken three months before death 
contained a typicallymphoproliferative lesion that was incorrectly 
diagnosed as non-specific reactive hyperplasia. The organs known 
to have been involved in each patient are summarised in table I. 
Infectious Disease Studies 
Serological evidence of active infection with the Epstein-Barr 
virus (EBV) was found near the time of the lymphoproliferative 
complication in 15 (880/0) of the 17 patients (table II). Although 
Epstein-Barr virus nuclear antigen (EBNA) was demonstrated in 
only 6 of 12 tumour specimens in which the appropriate touch 
preparation tests were obtained (table n), 7 of8 tumours examined 
by DNA hybridisation studies contained EBV genomes including 3 
that had negative EBNA touch preparations. The diagnosis of 
active EBV infection in 88% of these patients was about four times 
more frequent than documented by Ho et al9 in transplant patients 
(Pittsburgh experience) who did not have lymproliferative 
complications. Primary and reactivation EBV infections were 
almost equally represented. 
Other infections were catalogued that occurred just before, or at 
3 
the time of, the Iymphoproliferative complication (table I). 8 of the 
17 patients had no other infections and another 3 had only Herpes 
simplex. 6 of the 17 patients had severe contemporaneous infections 
which in 4 cases were a major factor in their deaths (table I). 
Histopathological Studies 
Formalin-fixed paraffin-embedded tissue was available for light 
microscopy in all 17 cases. Lymphomas were independently 
classified by 3 of the authors (M. A. N., R. ]., and K. A. P.) in 
accordance with the National Cancer Institute's working 
formulation of non-Hodgkin's lymphomas. 1O Sections were also 
stained for cytoplasmic immunoglobulin light and heavy chains by 
the avidin-biotin-peroxidase complex method of Hsu II with 
pronase digestion. Rabbit antisera specific for gamma, mu, delta, 
kappa, and lambda chains of immunoglobulins were obtained from 
Dakopatts, AJS Copenhagen, Denmark. Rabbit antisera specific for 
J chain and alpha chain came from Nordic Laboratories, Tilburg, 
the Netherlands. The specificity and optimum dilution of each 
antiserum were tested by double diffusion in agar and immuno-
electrophoresis and by use of specimens with plasmacytic mono-
clonal proliferation of known light and heavy chains. Sections were 
also stained for aI-antitrypsin and albumin. 
Frozen tissue was available in 12 cases and was used for the 
detection of EBNA by the anti-complement immunofluorescence 
technique 9 In 5 cases, specimens were taken for electron-
microscopy. These were fixed in 2% glutaraldehyde, post-fixed in 
osmium, and embedded in epoxy resin. 
Clonality of tumours was assessed by kappa:lambda light chain 
ratios independently determined in two separate laboratories by 
M. A. N. and K. A. P. A kappa:lambda ratio of 5:1 or greater was 
considered indicative· of monoclonal kappa proliferation. 
Conversely, a Jambda:kappa ratio of 3: I or greater implied mono-
clonal lambda proliferation. 
Results 
Nature of the Lesions 
By conventional histopathological criteria, 15 patients 
were diagnosed as having non-Hodgkin's diffuse malignant 
lymphoma. Of these, II were classified as large cell non-
cleaved, 3 as large cell immunoblastic, and I could not be 
further defined. The other 2 patients had atypical Iympho-
proliferation characterised by a predominance of plasma cells 
(table Ill). 
II of the IS lymphomas and both atypical Iympho-
proliferations were of B cell origin as judged by immuno-
globulin staining; in 4 lymphomas, immunoglobulins could 
not be demonstrated. Of the lymphomas, 3 were exclusively 
monoclonal, 4 were exclusively polycional, and 2 patients 
with several lymphoma nodules had both monoclonal and 
polyclonal lesions. 6 lymphomas could not be assessed 
because insufficient cells stained for light chains. Both 
patients with Iymphoproliferation had polyclonal lesions 
(table III). 
No viral particles were detected by electron microscopy in 
the 5 cases studied. 
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TABLE II-EPSTEIN·BARR VIRUS 
Heart or 
- Kidney Liver heart·lung Total cases 
Serological evidence of active 
EBV infection" 618 414 515 15/l7 
Primary 3 2 2 7 
Reactivation 3 2 3 8 
None 2t 2 
Tissue EBNA 115 212 315 6/12 
"In all 17 cases, sera were obtained before or at transplantation and at least at 
monthly intervals after transplantation. Primary infection was defined as 
serological conversion from a seronegative state for IgG against EBV virus 
capsid antigen (VCA) after transplantation to a seropositive state. Reactivation 
infection represented a four·fold or greater serological rise ofIgG anti·VCA. 
Primary and reactivation infections occurred before or around the time of 
tissue diagnosis of a lymphoproliferative lesion. 
t Evidence of old infection, but reactivation not clearly demonstrated. 
EBNA: Epstein·Barr virus nuclear antigen, looked for by immunofluorescent 
staining on touch preparations and frozen tissue sections. The 50% incidence 
of positive touch preparations was falsely low. EBV genomes were 
demonstrated in 7 of8 tumours (including 3 touch preparation negative) that 
were examined with DNA hybridisation techniques by J. Pagano (University 
of North Carolina), G. Miller (Yale), or M. A. Epstein (Bristol). 
Response to Therapy, Patient purviva~ and Graft Function 
Renal recipients.-l patient (case 2) who died of 
pneumonitis with a functioning graft had multifocal 
lymphomatous lesions at necropsy. The 7 patients in whom 
the diagnosis was made from biopsy specimens are alive and 
all are thought to be tumour-free. They had in common the 
reduction or discontinuance ofimmunosuppression (table I). 
In 4 of the 7, no chemotherapy or irradiation was used; 2 of 
these patients had monoclonal tumours. Only 1 of the 7 
surviving patients was treated with acyclovir. 
2 patients (cases 5 and 6) were treated with multiple chemo-
therapeutic agents (table I) and another (case 4) had 5400 rad 
cervical irradiation. Although the patients survived, we judge 
in retrospect that the decisions to use chemotherapy or 
irradiation may have been erroneous. 
5 of the 7 patients who survived had operations to relieve 
the complications of bowel perforation (5 instances) or 
prostatic obstruction (one instance) caused by the lympho-
proliferative disorders. In 3 of these patients whose immuno-
suppression was reduced or stopped, no remaining tumour 
could be found at reoperation 21f2 to 5 th weeks later (cases 
5-7). In 2 other patients (cases 4 and 8) with similar reduc-
tions of immunosuppression, no residual tumour could be 
found at repeat cervical node or endoscopic gastric biopsy 
after 3 and 4 weeks. 
The renal grafts on of the 7 survivors were rejected I week 
to I year after the reduction of immunosuppression. The 
kidneys of the other 4 recipients are functioning perfectly 
seven, seventeen, twenty-eight, and forty-three months later 
under low dose maintenance therapy with cyclosporin and 
prednisone. 
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Liver recipients.-The patient (case 10) in whom the 
diagnosis of a Iymphoproliferative tumour in a cervical node 
biopsy was missed eight months after transplantation, died in 
another hospital three and a half months later of airway 
obstruction, a few minutes after indirect laryngoscopy. 
Changes in immunosuppression had not been made. At 
necropsy the mesenteric and retroperitoneal nodes proved to 
contain the same kind oflymphoid tissue as had been present 
in the neck three months earlier. The diagnosis was plasma-
cytoid B cell hyperplasia (table IJI). The patient had been 
intermittently febrile for several months during which liver 
function had been normal. 
The diagnosis of a Iymphoproliferative disorder was made 
from biopsy specimens in the other 3 liver recipients, and the 
only treatment change was reduction of the cyclosporin and 
steroid doses (table I). 1 of these 3 patients (case 9), whose 
diagnosis was made by incomplete removal of a mass in the 
right kidney plus biopsy of a cervical lesion, had slow 
deterioration of hepatic function necessitating retrans-
plantation after four and a half months. There was only 
microscopic evidence of residual lymphoma then and at 
necropsy 3 weeks later after the patient had died of 
haemorrhagic pancreatitis and multiple other postoperative 
complications. 
A patient (case II) from whom five lymphoma-containing 
segments of bowel were removed at operation for intestinal 
obstruction had a rejection four months after the major 
reductions of immunosuppression shown in table I, but this 
was reversed with intensified therapy and he remains well 
and tumour-free more than a year after the diagnosis of the 
Iymphoproliferative complication. Another patient (case 12) 
recovered promptly after ileocolectomy for multiple tumours 
and bileduct reconstruction for partial biliary oDstructlon. 
With much lower doses of cyclosporin and prednisone (table 
I) there has been no rejection and she is thought to be tumour-
free. 
Heart or heart-lung reclpients.-Multifocal lymphomas 
were found at necropsy in a heart recipient (case 13) who died 
of cytomegalovirus pneumonitis. The other 4 patients had 
Iymphoproliferative complications diagnosed during life 
from biopsy of enlarged cervical or inguinal lymph nodes or 
from a tonsillectomy specimen. One of these patients (case 
16), a heart-lung recipient, later had perforation of the ileum 
from the same lymphopro!iferative process. The perforation 
was not diagnosed for several days and, despite emergency 
intestinal resection, he died of abdominal infection. Wide-
spread infection also caused the death of a heart recipient 
(case 14) who was given chemotherapy, regional irradiation, 
and acyclovir in preference to reduction ofimmunosuppres-
sion. The chemotherapy caused profound bone marrow 
depression; In both the foregoing heart and heart-lung 
recipients who died of widespread infection, residual 
Iymphoproliferative foci were present in lymph nodes and/or 
the gastrointestinal tract. Many of these lesions had areas of 
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necrosis. The transplanted organs which functioned until 
death had minor signs of rejection. 
A heart and heart-lung recipient each had tumour 
involution, the former (case IS) after conclusion of a course of 
ALG and reduction of cyclosporin and prednisone doses, and 
the latter (case 17) when the cyclosporin dose was drastically 
reduced (table I). No other treatment was given to the heart 
recipient. The heart-lung recipient had a course of acyclovir. 
Neither patient has had signs of rejectiorr in thesubsequent 
eight and four months. 
Discussion 
There is no reason to believe that the neoplasms in this 
report differ essentially from the post-transplantation 
"lymphomas" or "reticulum cell sarcomas", arising with 
conventional immunosuppression, that were compiled in the 
Denver Registry3 (now located in Cincinnati) or in the 
University of Minnesota collection of "lymphoproliferative 
disorders".6 By the National Cancer Institute 
classification, JO most of the lesions were B cell malignant 
lymphomas of diffuse large cell type; 2 were atypical B cell 
proliferations. 6 of the neoplasms were considered polyclonal 
and 3 monoclonal, and 2 further cases exhibited both types of 
clonality. Our criterion for kappa monoclonality was a 
kappa:lambda ratio of 5: I or greater and for lambda mono-
clonality a lambda:kappa ratio of 3: I or greater. However, 
there is no generally accepted standard for the diagnosis of 
monoclonality oflymphomas when the cytoplasmic immuno-
globulin staining technique is used. Some investigators insist 
that the tumour population must stain exclusively for one 
light chain and/or heavy chain. 12 Others regard the tumour as 
monoclonal if the number of cells expressing the 
predominant light chain type is more than five times the 
number of cells expressing the other light chain type. 13 Levy 
et al14 have used kappa:lambda and lambda:kappa surface 
immunoglobulin ratios of3: 1 and 2: I as the dividing line. For 
clonality to be firml y established, other investigations such as 
hybridisation studies with DNA light chain probes need to be 
done, as have been reported by Cleary et al. 15 These are being 
attempted on some of our specimens. 
We have long recommended drastic reduction or discon-
tinuance of immunosuppression in patients with post-
transplantation lymphomas or other explosively growing 
neoplasms.5, 16·18 The concept of treatment withdrawal has 
not been accepted or applied widely for the reasons most 
clearly enumerated and defended by Simmons and 
Najarian. 19 However, their approach, in which surgical 
extirpation, irradiation, chemotherapy, and most recently the 
antiviral drug acyclovir are the principal therapeutic tools, 
has had an overwhelming mortality.6 
In contrast, the simple expedient herein reported of stop-
ping or reducing immunosuppression in patients being 
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treated with cyclosporin and prednisone has led to prompt 
and seemingly permanent resolution oflymphoproliferative 
tumours-provided that complications such as intestinal 
perforation or infection could be controlled. The only 
patients among 12 kidney or liver recipients whose Iympho-
proliferative lesions were not controlled were 2 (1 in each 
recipient category) who were not appropriately treated 
because of failure to make the diagnosis. We speculate that 
accidental and unknowing reversal of Iymphoproliferative 
lesions may be a common event after transplantation since 
most renal transplant surgeons stop or greatly reduce 
immunosuppression if a patient becomes febrile and ill-an 
action that could not be better designed to abort an occult 
lymphoma. 
The complete disappearance of lymphoproliferative 
tumours on withdrawal of immunosuppression is not a 
special feature of cyclosporin-steroid therapy. The same 
thing was described long ago after reduction or withdrawal of 
azathioprine, prednisone, and antilymphocyte globulin l6,17 
and documented in detail by Iwatsuki et al 18 and Geis et aJ.5 
Of the 5 patients reported by Geis5 and Iwatsuki l8 and their 
associates whose lymphomas regressed, I later acquired a 
different neoplasm and the other 4 remained tumour free. 20 
As with kidney and liver recipients, the only survivors 
among the 5 heart or heart-lung recipients in the present 
series were 2 who had withdrawal of immunosuppression. In 
I of the other 3, the diagnosis was not made until necropsy. A 
missed intestinal perforation and overwhelming infection 
precluded survival in another, and the third had continuation 
of cyclosporin and steroid plus treatment with 
chemotherapeutic agents which themselves can be 
immunosuppressive and toxic and which are probably 
contraindicated. 
It is noteworthy with all three of the organs that reduction 
or even suspension .of immunosuppression for long periods 
was not necessarily accompanied by irreversible transplant 
rejection. Most of the grafts were rescued along with the 
patients, as would have been expected if the development of a 
Iymphoproliferative complication was presumptive evidence 
of over-immunosuppression. This observation should 
encourage further trials of this approach in liver or cardiac 
recipients, despite the natural apprehension that the penalty 
of treatment withdrawal might be a lethal rejection of the 
graft. 
A popular hypothesis4,21 has been that lymphomatous 
neoplasms develop when B lymphocytes that are infected 
with Epstein-Barr virus are liberated by efficient 
immunosuppression frorn the control of one or more kinds of 
T lymphocytes, allowing uninhibited proliferation. The 
theory continues that one of the rapidly multiplying B clones 
can undergo a chromosomal translocation, making it an 
autonomous monoclonal malignancy not easily influenced by 
immunological reconstitution or other therapy.6,21 Whether 
such translocations occurred in the tumours described here is 
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under study. However, it should be noted that in our series 
several seemingly monoclonal lesions involuted as readily as 
the polyclonal neoplasms. 
The association of the lymphomas in our cases with an EBV 
infection was the same as that reported by Hanto et al6 from 
the University of Minnesota. However, the principle of 
treating a malignancy by allowing recovery from 
immunosuppression may have application beyond EBV-
induced neoplasms-as has been suggested by observations 
with multifocal Kaposi's sarcoma, a, cytomegalovirus 
associated tumour.22 2 of our renal recipients whose 
cyclosporin-steroid therapy was drastically reduced have had 
stabilisation or complete reversal of multifocal Kaposi 
tumours without loss of graft function; the longest follow-up 
with a complete "cure" is almost 2 years. 23 The way in which 
tumours develop under immunosuppression and can be 
reversed by a reduction or cessation of therapy should 
provide' insight into, and encouragement for trial of 
immunostimulation techniques in treating, natural acquired 
immunodeficiency syndromes (AIDS). 
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